Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 151

Similar articles for PubMed (Select 17896144)

1.

A highly active and tolerable neoadjuvant regimen combining paclitaxel, carboplatin, 5-FU, and radiation therapy in patients with stage II and III esophageal cancer.

van de Schoot L, Romme EA, van der Sangen MJ, Creemers GJ, van Lijnschoten G, van Driel OJ, Rutten HJ, Nieuwenhuijzen GA.

Ann Surg Oncol. 2008 Jan;15(1):88-95. Epub 2007 Sep 26.

2.

Preoperative carboplatin and paclitaxel-based chemoradiotherapy for esophageal carcinoma: results of a modified CROSS regimen utilizing radiation doses greater than 41.4 Gy.

Nabavizadeh N, Shukla R, Elliott DA, Mitin T, Vaccaro GM, Dolan JP, Maggiore RJ, Schipper PH, Hunter JG, Thomas CR Jr, Holland JM.

Dis Esophagus. 2015 Jun 5. doi: 10.1111/dote.12377. [Epub ahead of print]

PMID:
26043837
3.

[The value of intraluminal brachytherapy in the treatment for esophageal cancer].

Kanaev SV, Tyuryaeva EI, Levchenko EV, Dvoretsky SY, Shcherbakov AM, Avanesyan AA.

Vopr Onkol. 2015;61(1):34-9. Russian.

PMID:
26016143
4.

Low-dose fractionated radiation and chemotherapy prior to definitive chemoradiation in locally advanced carcinoma of the uterine cervix: Results of a prospective phase II clinical trial.

Das S, Subhashini J, Rami Reddy JK, KantiPal S, Isiah R, Oommen R.

Gynecol Oncol. 2015 May 23. pii: S0090-8258(15)00935-X. doi: 10.1016/j.ygyno.2015.05.020. [Epub ahead of print]

PMID:
26013695
5.

How well does pathologic stage predict survival for esophageal adenocarcinoma after neoadjuvant therapy?

Kim JY, Nelson RA, Kim J, Raz D.

J Thorac Dis. 2015 Apr;7(4):734-9. doi: 10.3978/j.issn.2072-1439.2015.04.30.

6.
7.

Results of Neoadjuvant Chemoradiotherapy With Docetaxel and 5-Fluorouracil Followed by Esophagectomy to Treat Locally Advanced Esophageal Cancer.

Hamai Y, Hihara J, Emi M, Murakami Y, Kenjo M, Nagata Y, Okada M.

Ann Thorac Surg. 2015 Jun;99(6):1887-93. doi: 10.1016/j.athoracsur.2015.02.042. Epub 2015 Apr 23.

PMID:
25912745
8.

Outcomes of patients with squamous cell carcinoma of esophagus who did not receive surgical resection after neoadjuvant radiochemotherapy.

Fakhrian K, Ordu AD, Nieder C, Lordick F, Kup PG, Theisen J, Combs SE, Geinitz H.

Tumori. 2015 Jun 25;101(3):263-7. doi: 10.5301/tj.5000266. Epub 2015 Apr 16.

PMID:
25908044
9.

Radiation dose does not influence anastomotic complications in patients with esophageal cancer treated with neoadjuvant chemoradiation and transhiatal esophagectomy.

Koëter M, van der Sangen MJ, Hurkmans CW, Luyer MD, Rutten HJ, Nieuwenhuijzen GA.

Radiat Oncol. 2015 Mar 6;10:59. doi: 10.1186/s13014-015-0361-4.

10.

NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma.

Mukherjee S, Hurt CN, Gwynne S, Bateman A, Gollins S, Radhakrishna G, Hawkins M, Canham J, Lewis W, Grabsch HI, Sharma RA, Wade W, Maggs R, Tranter B, Roberts A, Sebag-Montefiore D, Maughan T, Griffiths G, Crosby T.

BMC Cancer. 2015 Feb 12;15:48. doi: 10.1186/s12885-015-1062-y.

11.

Reduction of heart volume during neoadjuvant chemoradiation in patients with resectable esophageal cancer.

Haj Mohammad N, Kamphuis M, Hulshof MC, Lutkenhaus LJ, Gisbertz SS, Bergman JJ, de Bruin-Bon HA, Geijsen ED, Bel A, Boekholdt SM, van Laarhoven HW.

Radiother Oncol. 2015 Jan;114(1):91-5. doi: 10.1016/j.radonc.2014.12.005. Epub 2015 Jan 24.

PMID:
25630429
12.

Induction chemotherapy followed by surgery for advanced oesophageal cancer.

Toxopeus EL, Talman S, van der Gaast A, Spaander VM, van Rij CM, Krak NC, Biermann K, Tilanus HW, Mathijssen RH, van Lanschot JJ, Wijnhoven BP.

Eur J Surg Oncol. 2015 Mar;41(3):323-32. doi: 10.1016/j.ejso.2014.11.043. Epub 2014 Dec 3.

PMID:
25534280
13.

Association between radiation dose and pathological complete response after preoperative radiochemotherapy in esophageal squamous cell cancer.

Ordu AD, Nieder C, Geinitz H, Scherer V, Kup PG, Schuster T, Combs SE, Fakhrian K.

Anticancer Res. 2014 Dec;34(12):7255-61.

PMID:
25503157
14.

Predicting response to neoadjuvant therapy in esophageal cancer with p53 genotyping: a fortune-teller's crystal ball or a viable prognostic tool?

Nason KS.

J Thorac Cardiovasc Surg. 2014 Nov;148(5):2286-7. doi: 10.1016/j.jtcvs.2014.09.036. Epub 2014 Sep 18. No abstract available.

PMID:
25444198
15.

Which is the best postoperative chemotherapy regimen in patients with rectal cancer after neoadjuvant therapy?

Gao P, Song YX, Sun JX, Chen XW, Xu YY, Zhao JH, Huang XZ, Xu HM, Wang ZN.

BMC Cancer. 2014 Nov 27;14:888. doi: 10.1186/1471-2407-14-888.

16.

Prospective, open, multicentre Phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and cisplatin for esophageal carcinoma.

Ma HB, Di ZL, Wen J, Ke Y, Sun X, Ren J.

Jpn J Clin Oncol. 2015 Feb;45(2):169-75. doi: 10.1093/jjco/hyu181. Epub 2014 Nov 21.

PMID:
25416813
17.

Prognostic classification of histopathologic response to neoadjuvant therapy in esophageal adenocarcinoma.

Hölscher AH, Drebber U, Schmidt H, Bollschweiler E.

Ann Surg. 2014 Nov;260(5):779-84; discussion 784-5. doi: 10.1097/SLA.0000000000000964.

PMID:
25379849
18.

Neoadjuvant therapy for esophageal cancer.

Shah RD, Cassano AD, Neifeld JP.

World J Gastrointest Oncol. 2014 Oct 15;6(10):403-6. doi: 10.4251/wjgo.v6.i10.403. Review.

19.

Preoperative chemoradiation therapy in combination with panitumumab for patients with resectable esophageal cancer: the PACT study.

Kordes S, van Berge Henegouwen MI, Hulshof MC, Bergman JJ, van der Vliet HJ, Kapiteijn E, van Laarhoven HW, Richel DJ, Klinkenbijl JH, Meijer SL, Wilmink JW.

Int J Radiat Oncol Biol Phys. 2014 Sep 1;90(1):190-6. doi: 10.1016/j.ijrobp.2014.05.022.

PMID:
25195993
20.

Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: comparison of 2 commonly used scoring approaches.

Karamitopoulou E, Thies S, Zlobec I, Ott K, Feith M, Slotta-Huspenina J, Lordick F, Becker K, Langer R.

Am J Surg Pathol. 2014 Nov;38(11):1551-6. doi: 10.1097/PAS.0000000000000255.

PMID:
25140894
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk